Bing Melody Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bing Melody Zhang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
James L. Zehnder
Department of Pathology, Stanford University School of Medicine, Stanford, California
4 shared publications- David Shyr
School of Medicine, Stanford University, Stanford, CA 94305, USA
3 shared publications - Jack K. Tung
Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
3 shared publications Chandler C. Ho
Molecular Pathology Laboratory, Stanford Health Care, Stanford, California
2 shared publicationsDiwash Jangam
Molecular Pathology Laboratory, Stanford Health Care, Stanford, California, USA
2 shared publications- Gopin Saini
Stem Cell and Gene Therapy Clinical Trial Program, Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
2 shared publications
Latest Publications
- 22 March 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70115
Intraoperative Therapeutic Plasma Exchange for Sensitized Heart Transplant Candidates
Donor specific human leukocyte antigen antibodies are associated with increased risk of rejection, worse post‐transplant outcomes, and longer waitlist times due to the immunological risks. Intraoperative therapeutic plasma exchange (iTPE) represents a potential strategy to mitigate the immunological risk. This study aims to evaluate the clinical outcomes associated with the use of iTPE in sensitized heart transplant recipients. This retrospective, single‐center cohort study included 59 adult heart transplant recipients. Patients were categorized into three groups: those receiving iTPE ( n = 20), sensitized patients without iTPE ( n = 19), and unsensitized patients ( n = 20). We assessed recipient survival, antibody‐mediated rejection (AMR) and infection free survival, waitlist time, and length of intensive care unit (ICU) and hospital stay. The overall cohort had a median age of 58 years with predominantly female patients (61%). The iTPE group exhibited a higher percentage of donor specific antibody positive and positive flow cytometry crossmatch results. Unsensitized patients had shorter wait times, but there was no difference between the iTPE and sensitized groups. There was no statistically significant difference in ICU and hospital stay, one‐year and three‐year survival, and AMR‐free survival among the groups. The iTPE group had the lowest infection‐free survival at 1 year. In conclusion, we report that iTPE may serve as an effective adjunct to immunosuppressive therapy for higher immunological risk heart transplant recipients with comparable AMR‐free survival, 1‐ and 3‐year survival. However, increased susceptibility to infections with iTPE underscores the infection management strategies post‐transplant. Larger, multi‐center cohort studies are necessary.
- 22 March 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70115
Intraoperative Therapeutic Plasma Exchange for Sensitized Heart Transplant Candidates
Donor specific human leukocyte antigen antibodies are associated with increased risk of rejection, worse post‐transplant outcomes, and longer waitlist times due to the immunological risks. Intraoperative therapeutic plasma exchange (iTPE) represents a potential strategy to mitigate the immunological risk. This study aims to evaluate the clinical outcomes associated with the use of iTPE in sensitized heart transplant recipients. This retrospective, single‐center cohort study included 59 adult heart transplant recipients. Patients were categorized into three groups: those receiving iTPE ( n = 20), sensitized patients without iTPE ( n = 19), and unsensitized patients ( n = 20). We assessed recipient survival, antibody‐mediated rejection (AMR) and infection free survival, waitlist time, and length of intensive care unit (ICU) and hospital stay. The overall cohort had a median age of 58 years with predominantly female patients (61%). The iTPE group exhibited a higher percentage of donor specific antibody positive and positive flow cytometry crossmatch results. Unsensitized patients had shorter wait times, but there was no difference between the iTPE and sensitized groups. There was no statistically significant difference in ICU and hospital stay, one‐year and three‐year survival, and AMR‐free survival among the groups. The iTPE group had the lowest infection‐free survival at 1 year. In conclusion, we report that iTPE may serve as an effective adjunct to immunosuppressive therapy for higher immunological risk heart transplant recipients with comparable AMR‐free survival, 1‐ and 3‐year survival. However, increased susceptibility to infections with iTPE underscores the infection management strategies post‐transplant. Larger, multi‐center cohort studies are necessary.
- Open Access
Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation
- Open Access
- 3 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Immune repertoire profiling uncovers pervasive T cell clonal expansions in benign prostatic hyperplasia
We discovered T-cell clonal expansions in benign prostatic hyperplasia, indicative of a specific adaptive immune response and with implications for disease pathogenesis and new treatments.
- 3 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Open AccessImmune repertoire profiling uncovers pervasive T cell clonal expansions in benign prostatic hyperplasia
We discovered T-cell clonal expansions in benign prostatic hyperplasia, indicative of a specific adaptive immune response and with implications for disease pathogenesis and new treatments.
- 30 March 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (6) , 465-474
Performance Evaluation of a Next-Generation Sequencing–Based T-Cell Receptor Gene Rearrangement Assay
- 30 March 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (6) , 465-474
Performance Evaluation of a Next-Generation Sequencing–Based T-Cell Receptor Gene Rearrangement Assay
- Open Access
- 10 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4021
Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
Background. Leukemic relapse remains the primary cause of treatment failure and death after allogeneic hematopoietic stem cell transplant. Changes in post-transplant donor chimerism have been identified as a predictor of relapse. A better predictive model of relapse incorporating donor chimerism has the potential to improve leukemia-free survival by allowing earlier initiation of post-transplant treatment on individual patients. We explored the use of machine learning, a suite of analytical methods focusing on pattern recognition, to improve post-transplant relapse prediction. Methods. Using a cohort of 63 pediatric patients with acute lymphocytic leukemia (ALL) and 46 patients with acute myeloid leukemia (AML) who underwent stem cell transplant at a single institution, we built predictive models of leukemic relapse with both pre-transplant and post-transplant patient variables (specifically lineage-specific chimerism) using the random forest classifier. Local Interpretable Model-Agnostic Explanations, an interpretable machine learning tool was used to confirm our random forest classification result. Results. Our analysis showed that a random forest model using these hyperparameter values achieved 85% accuracy, 85% sensitivity, 89% specificity for ALL, while for AML 81% accuracy, 75% sensitivity, and 100% specificity at predicting relapses within 24 months post-HSCT in cross validation. The Local Interpretable Model-Agnostic Explanations tool was able to confirm many variables that the random forest classifier identified as important for the relapse prediction. Conclusions. Machine learning methods can reveal the interaction of different risk factors of post-transplant leukemic relapse and robust predictions can be obtained even with a modest clinical dataset. The random forest classifier distinguished different important predictive factors between ALL and AML in our relapse models, consistent with previous knowledge, lending increased confidence to adopting machine learning prediction to clinical management.
- 10 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4021
Open AccessExploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
Background. Leukemic relapse remains the primary cause of treatment failure and death after allogeneic hematopoietic stem cell transplant. Changes in post-transplant donor chimerism have been identified as a predictor of relapse. A better predictive model of relapse incorporating donor chimerism has the potential to improve leukemia-free survival by allowing earlier initiation of post-transplant treatment on individual patients. We explored the use of machine learning, a suite of analytical methods focusing on pattern recognition, to improve post-transplant relapse prediction. Methods. Using a cohort of 63 pediatric patients with acute lymphocytic leukemia (ALL) and 46 patients with acute myeloid leukemia (AML) who underwent stem cell transplant at a single institution, we built predictive models of leukemic relapse with both pre-transplant and post-transplant patient variables (specifically lineage-specific chimerism) using the random forest classifier. Local Interpretable Model-Agnostic Explanations, an interpretable machine learning tool was used to confirm our random forest classification result. Results. Our analysis showed that a random forest model using these hyperparameter values achieved 85% accuracy, 85% sensitivity, 89% specificity for ALL, while for AML 81% accuracy, 75% sensitivity, and 100% specificity at predicting relapses within 24 months post-HSCT in cross validation. The Local Interpretable Model-Agnostic Explanations tool was able to confirm many variables that the random forest classifier identified as important for the relapse prediction. Conclusions. Machine learning methods can reveal the interaction of different risk factors of post-transplant leukemic relapse and robust predictions can be obtained even with a modest clinical dataset. The random forest classifier distinguished different important predictive factors between ALL and AML in our relapse models, consistent with previous knowledge, lending increased confidence to adopting machine learning prediction to clinical management.
- Open Access
- 16 May 2024
- Published by MDPI AG in Preprints.org
Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
In this report, we present a study demonstrating how machine learning methods can reveal the interaction of different risk factors of post-transplant leukemic relapse and obtain robust predictions even with a modest clinical dataset. Using a cohort of 63 pediatric patients with acute lymphocytic leukemia (ALL) and 46 patients with acute myeloid leukemia (AML) who underwent stem cell transplant at a single institution, we built predictive models of leukemic relapse with both pretransplant and posttransplant patient variables (specifically lineage-specific chimerism) using the random forest classifier. The random forest classifier revealed different important predictive factors between ALL and AML in our relapse models consistent with previous knowledge. Furthermore, it also distinguished donor CD34 chimerism as most impactful in relapse prediction compare to donor chimerism of other cellular lineages in our dataset for ALL but CD3 for AML. Our models greatly improved sensitivity and specificity at predicting relapses in cross validation compared to a reference model based on our own institutional incidence of relapse and inferential statistical principles. Local Interpretable Model-Agnostic Explanations, an interpretable machine learning tool, confirmed our Random Forest Classification result and provided an intuitive explanation of how our machine learning models made the relapse prediction for each individual patient.
- 16 May 2024
- Published by MDPI AG in Preprints.org
Open AccessExploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
In this report, we present a study demonstrating how machine learning methods can reveal the interaction of different risk factors of post-transplant leukemic relapse and obtain robust predictions even with a modest clinical dataset. Using a cohort of 63 pediatric patients with acute lymphocytic leukemia (ALL) and 46 patients with acute myeloid leukemia (AML) who underwent stem cell transplant at a single institution, we built predictive models of leukemic relapse with both pretransplant and posttransplant patient variables (specifically lineage-specific chimerism) using the random forest classifier. The random forest classifier revealed different important predictive factors between ALL and AML in our relapse models consistent with previous knowledge. Furthermore, it also distinguished donor CD34 chimerism as most impactful in relapse prediction compare to donor chimerism of other cellular lineages in our dataset for ALL but CD3 for AML. Our models greatly improved sensitivity and specificity at predicting relapses in cross validation compared to a reference model based on our own institutional incidence of relapse and inferential statistical principles. Local Interpretable Model-Agnostic Explanations, an interpretable machine learning tool, confirmed our Random Forest Classification result and provided an intuitive explanation of how our machine learning models made the relapse prediction for each individual patient.
- Open Access
- 2 March 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (6) , 331-341
Minimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor
- 2 March 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (6) , 331-341
Open AccessMinimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor
- Top Cited PapersOpen Access
- 10 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (20) , 2417-2429
The role of CD8+ T cell clones in immune thrombocytopenia
Immune thrombocytopenia (ITP) is traditionally considered an antibody-mediated disease. However, a number of features suggest alternative mechanisms of platelet destruction. In this study, we use a multi-dimensional approach to explore the role of cytotoxic CD8+ T cells in ITP. We characterised patients with ITP and compared them to age-matched controls using immunophenotyping, next-generation sequencing of T cell receptor (TCR) genes, single-cell RNA sequencing, and functional T cell and platelet assays. We found that adults with chronic ITP have increased polyfunctional, terminally differentiated effector memory CD8+ T cells (CD45RA+CD62L-) expressing intracellular interferon-g, tumour necrosis factor-a, and Granzyme B defining them as TEMRA cells. These TEMRA cells expand when the platelet count falls and show no evidence of physiological exhaustion. Deep sequencing of the T cell receptor showed expanded T cell clones in patients with ITP. T cell clones persisted over many years, were more prominent in patients with refractory disease, and expanded when the platelet count was low. Combined single-cell RNA and TCR sequencing of CD8+ T cells confirmed that the expanded clones are TEMRA cells. Using in vitro model systems, we show that CD8+ T cells from patients with ITP form aggregates with autologous platelets, release interferon-g and trigger platelet activation and apoptosis through TCR-mediated release of cytotoxic granules. These findings of clonally expanded CD8+ T cells causing platelet activation and apoptosis provide an antibody-independent mechanism of platelet destruction, indicating that targeting specific T-cell clones could be a novel therapeutic approach for patients with refractory ITP.
- 10 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (20) , 2417-2429
Top Cited PapersOpen AccessThe role of CD8+ T cell clones in immune thrombocytopenia
Immune thrombocytopenia (ITP) is traditionally considered an antibody-mediated disease. However, a number of features suggest alternative mechanisms of platelet destruction. In this study, we use a multi-dimensional approach to explore the role of cytotoxic CD8+ T cells in ITP. We characterised patients with ITP and compared them to age-matched controls using immunophenotyping, next-generation sequencing of T cell receptor (TCR) genes, single-cell RNA sequencing, and functional T cell and platelet assays. We found that adults with chronic ITP have increased polyfunctional, terminally differentiated effector memory CD8+ T cells (CD45RA+CD62L-) expressing intracellular interferon-g, tumour necrosis factor-a, and Granzyme B defining them as TEMRA cells. These TEMRA cells expand when the platelet count falls and show no evidence of physiological exhaustion. Deep sequencing of the T cell receptor showed expanded T cell clones in patients with ITP. T cell clones persisted over many years, were more prominent in patients with refractory disease, and expanded when the platelet count was low. Combined single-cell RNA and TCR sequencing of CD8+ T cells confirmed that the expanded clones are TEMRA cells. Using in vitro model systems, we show that CD8+ T cells from patients with ITP form aggregates with autologous platelets, release interferon-g and trigger platelet activation and apoptosis through TCR-mediated release of cytotoxic granules. These findings of clonally expanded CD8+ T cells causing platelet activation and apoptosis provide an antibody-independent mechanism of platelet destruction, indicating that targeting specific T-cell clones could be a novel therapeutic approach for patients with refractory ITP.
- 1 July 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (7) , 805-815
Validation of a Next-Generation Sequencing–Based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay
- 1 July 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (7) , 805-815
Validation of a Next-Generation Sequencing–Based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay
- 5 January 2021
- Published by Taylor & Francis in Platelets
- Vol. 32 (8) , 1108-1112
Identification of a pathogenic TUBB1 variant in a Chinese family with congenital macrothrombocytopenia through whole genome sequencing
Congenital macrothrombocytopenia is a genetically heterogeneous group of rare disorders. We herein report a large Chinese family presented with phenotypic variability involving thrombocytopenia and/or giant platelets. Whole genome sequencing (WGS) of the proband and one of his affected brothers identified a potentially pathogenic c.952 C > T heterozygous variant in the TUBB1 gene. This p.R318W β1-tubulin variant was also identified in three additional siblings and five members of the next generation. These findings were consistent with an autosomal dominant inheritance with incomplete penetrance. Moreover, impaired platelet agglutination in response to ristocetin was detected in the patient’s brother. Half of the family members harboring the p.R318W mutation displayed significantly decreased external release of p-selectin by stimulated platelets. The p.R318W β1-tubulin mutation was identified for the first time in a Chinese family with congenital macrothrombocytopenia using WGS as an unbiased sequencing approach. Affected individuals within the family demonstrated impaired platelet aggregation and/or release functions.
- 5 January 2021
- Published by Taylor & Francis in Platelets
- Vol. 32 (8) , 1108-1112
Identification of a pathogenic TUBB1 variant in a Chinese family with congenital macrothrombocytopenia through whole genome sequencing
Congenital macrothrombocytopenia is a genetically heterogeneous group of rare disorders. We herein report a large Chinese family presented with phenotypic variability involving thrombocytopenia and/or giant platelets. Whole genome sequencing (WGS) of the proband and one of his affected brothers identified a potentially pathogenic c.952 C > T heterozygous variant in the TUBB1 gene. This p.R318W β1-tubulin variant was also identified in three additional siblings and five members of the next generation. These findings were consistent with an autosomal dominant inheritance with incomplete penetrance. Moreover, impaired platelet agglutination in response to ristocetin was detected in the patient’s brother. Half of the family members harboring the p.R318W mutation displayed significantly decreased external release of p-selectin by stimulated platelets. The p.R318W β1-tubulin mutation was identified for the first time in a Chinese family with congenital macrothrombocytopenia using WGS as an unbiased sequencing approach. Affected individuals within the family demonstrated impaired platelet aggregation and/or release functions.